LRMR Larimar Therapeutics
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 20, 2021
Larimar Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
Three Bala Plaza East, Suite 506
Bala Cynwyd, Pennsylvania
|(Address of principal executive offices)||(Zip Code)|
Registrant’s telephone number, including area code: (844) 511-9056
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
|Common Stock, par value $0.001 per share||LRMR||Nasdaq Global Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On May 20, 2021, Larimar Therapeutics, Inc. issued a press release announcing that the European Medicines Agency has granted Priority Medicines (PRIME) designation to CTI-1601 for the treatment of Friedreich’s ataxia (FA). A copy of this press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.
Financial Statements and Exhibits.
Below is a list of exhibits included with this Current Report on Form 8-K.
|99.1||Press Release of Larimar Therapeutics, Inc., dated May 20, 2021*|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Larimar Therapeutics, Inc.|
/s/ Carole S. Ben-Maimon, M.D.
|Name:||Carole S. Ben-Maimon, M.D.|
|Title:||President and Chief Executive Officer|
Date: May 21, 2021